Yes, in most cases you can. Hormone therapy and weight loss medications are not forbidden together, and neither the Zepbound nor the Wegovy label lists hormone therapy as a contraindication (1,2). What changes the answer is the form of estrogen you take, your clot and gallbladder history, and what you expect the hormones to do, because they are prescribed for hot flashes, vaginal symptoms and bone loss, not for weight.

That last point trips people up, so it gets its own section first.

Does hormone therapy make weight loss drugs work better?

Maybe. The evidence is thin, and it is observational.

The first signal came from a 2024 retrospective cohort in Menopause: 16 postmenopausal women on hormone therapy and 90 not on it, all taking semaglutide. At 12 months the hormone therapy group had lost 16 percent of body weight versus 12 percent, and the gap survived adjustment for confounders (3). A Mayo Clinic cohort followed with tirzepatide. After matching, 40 women using hormone therapy were compared with 80 who were not, and at a median of 18 months the hormone therapy group had lost 17 percent versus 14 percent. Forty-five percent of them reached a loss of 20 percent or more, against 18 percent of the others (4,5).

A larger analysis presented at the 2026 Menopause Society meeting in October, led by Regina Castaneda at Mayo Clinic Florida, covered nearly 2,400 women on semaglutide and nearly 1,500 on tirzepatide. Hormone therapy was linked to greater, sustained loss with semaglutide. With tirzepatide, users lost more early, but the final difference was not statistically significant (6).

Here is where I part ways with the headlines. Women who choose hormone therapy differ from women who do not. They may sleep better once the night sweats stop, which makes diet and exercise easier, and the Mayo authors say plainly that they cannot say hormone therapy caused the extra loss (4). A Spanish Menopause Society position statement calls the association hypothesis-generating and says weight loss alone is no reason to start hormone therapy (7). A 2026 clinical review lands in the same place (5). I agree.

A randomized answer is on the way. A registered trial of 96 early postmenopausal women compares Wegovy alone, a transdermal estradiol patch with micronized progesterone alone, and the two together (8). Until it reports, treat the synergy as an interesting idea rather than a plan. Tirzepatide already works at every reproductive stage, with about 23 percent loss in the peri- and postmenopausal groups of SURMOUNT-1 against 3 percent on placebo (9).

Will a weight loss medication stop my estrogen or progesterone from absorbing?

It might for a few weeks, and the answer depends on the drug and on whether the hormone is swallowed.

GLP-1 and dual agonist drugs slow gastric emptying. With tirzepatide the delay is largest after the first dose and fades with continued use (1). That matters for anything taken by mouth. The Zepbound label tells women on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase, and says non-oral hormonal contraceptives should not be affected (1). The data come from one 5 mg tirzepatide dose given with a combined pill of ethinyl estradiol and norgestimate. Peak levels fell 55 to 66 percent, but total exposure fell only 20 to 23 percent, and peak time slipped 2.5 to 4.5 hours (1).

Does that apply to menopausal doses? Nobody has tested it. Lilly states there is no information on tirzepatide in people taking oral hormone replacement therapy (10). A 2026 Maturitas review looked at tirzepatide and oral progestogens specifically and called an interaction biologically plausible but unproven, noting that no pharmacokinetic data exist for the progestogens used in menopause care and that any risk would cluster around initiation and dose escalation (11). There is one published case report, a 51-year-old woman on oral estrogen whose hot flashes and mood worsened during semaglutide titration and settled when the titration was slowed (12). One case proves nothing, but it fits the mechanism.

The other drugs differ. Wegovy’s label reports no clinically significant change in ethinyl estradiol or levonorgestrel levels with semaglutide tablets at steady state, and says semaglutide injection at 1 mg weekly did not affect absorption of oral medications in its clinical pharmacology trials (2). The same label tells patients to wait at least 30 minutes after the tablet before taking any other oral medication, which in practice means the morning estradiol pill waits (2). Foundayo, the orforglipron tablet I prescribe, can be taken with or without food, yet its label also warns about delayed gastric emptying and gives the same 30-day backup advice for oral contraceptives. Lilly calls that precautionary: modeling predicted a minor drop in peak level and no change in total exposure, and no trial has measured it (13,14).

My practical read is an extrapolation, so weigh it that way. If a woman needs systemic estrogen while starting a GLP-1 or tirzepatide, a patch, gel or spray skips the stomach entirely and the question goes away. If she prefers oral estradiol, starting it is reasonable, but watch for hot flashes or breakthrough bleeding creeping back during titration, and slow the escalation before raising the estrogen, which is what resolved the one reported case. Progesterone deserves a quiet eye too. A woman with a uterus whose bleeding pattern changes at dose steps on oral progesterone should be asked about it, because protecting the lining is the progestogen’s whole job.

I start most women on transdermal estradiol, usually a 0.025 mg patch changed twice a week, and go higher if the symptoms are more disruptive. A patch bypasses the gut and carries less clotting risk than oral estrogen. If she still has a uterus, she needs endometrial protection. For most women I start with separate products, usually a low-dose estradiol patch plus micronized progesterone, because I can adjust each hormone independently. The weight loss drug can change that. I draw a distinction between semaglutide and Foundayo or tirzepatide, where the concern about oral progesterone absorption is greater because of slowed gastric emptying. With Foundayo or tirzepatide, I discuss a levonorgestrel IUD or a combined estrogen-progestin patch to avoid uncertain oral progesterone absorption. The combined patch can be prescribed by telemedicine, which is why it is the one I normally use in that situation, but its lowest strength delivers 0.05 mg of estradiol per day, twice my usual starting dose. That trade-off needs to be discussed rather than treated as an automatic choice.

At the 8 to 12 week follow-up, I adjust for symptoms, bleeding, or side effects. If she feels well, I don’t change anything. If hot flashes or night sweats persist, we may raise the estradiol one step. I don’t adjust the dose for weight loss, and I don’t check routine hormone levels.

Why the route of estrogen matters more than the brand of weight loss drug

Setting absorption aside, route changes two other risks that run high in women with obesity.

Clots first. In a UK nested case-control study of more than 80,000 women with venous thromboembolism, oral hormone therapy raised the odds by 58 percent (adjusted OR 1.58), while transdermal preparations did not (OR 0.93, 95% CI 0.87 to 1.01). Estradiol carried less risk than conjugated equine estrogen, and medroxyprogesterone combinations were worst (OR 2.10) (15). Women with obesity carry a higher baseline clot risk on their own (5), which is why a joint FIGO and World Heart Federation paper calls transdermal estrogen with micronized progesterone or dydrogesterone the safest regimen for women at high thromboembolic risk (16). That is not a reason to refuse hormones to a woman with a BMI of 38. It is a reason to reach for the patch first.

Gallbladder second, and this one is a true stacking problem. The labels for tirzepatide and semaglutide both warn about acute gallbladder disease. In the Zepbound weight trials cholecystitis occurred in 0.7 percent versus 0.2 percent on placebo, and in Wegovy injection trials cholelithiasis ran 1.6 percent versus 0.7 percent, with the excess persisting even after accounting for how much weight was lost (1,2). Foundayo’s cholelithiasis rate was 1.0 versus 0.7 percent (13). Oral estrogen piles on. An estradiol tablet label cites a 2 to 4 fold increase in gallbladder disease requiring surgery (17), and in the Million Women Study current oral users had a relative risk of 1.74 for gallbladder admission against 1.17 for transdermal users (18). Rapid weight loss itself promotes stones (2). Three pushes in one direction is a good argument for the transdermal route in any woman with gallstone history.

Do the side effects overlap?

Mostly in the stomach. In Foundayo’s pooled obesity trials, nausea ran 26 to 35 percent by dose against 10 percent on placebo, vomiting 13 to 24 percent against 4, constipation 20 to 27 against 9, and diarrhea 21 to 25 against 11, mostly during dose escalation and easing afterward (13). Oral estradiol lists nausea, vomiting, abdominal cramps and bloating among its reported effects (17). Start both in the same week and feel awful, and nobody can say which pill is responsible. Staggering the starts, or choosing a patch, keeps the picture readable.

Thyroid medication is the interaction people forget. Estrogen raises thyroid-binding globulin, so a woman on levothyroxine may need more of it (17). Oral semaglutide raised levothyroxine exposure by 33 percent in the Wegovy label (2), and a 2026 case report describes thyrotoxic over-replacement after 48 pounds of weight loss on tirzepatide (19). Opposing forces act on the same woman, so a TSH recheck a few months in is cheap insurance.

What happens to muscle and bone?

This is the part of the combination with a plausible upside, and the least data.

Weight loss on these drugs costs lean mass along with fat. In the SURMOUNT-1 DXA substudy about 75 percent of the weight lost was fat and 25 percent lean, the same split as placebo (20). A 2026 meta-analysis found a consistent drop in lean mass with GLP-1 drugs that mostly tracked the weight loss, with no significant effect on bone outcomes and low certainty about whether the lean mass change harms function (21).

Bone is the open question for postmenopausal women. In the Look AHEAD substudy of postmenopausal women with type 2 diabetes, a 14 percent fall in estradiol during intensive lifestyle weight loss mediated a decline in whole-body bone density (22). Hormone therapy has proven bone effects, and the 2022 Menopause Society statement says it prevents bone loss and fracture (23). Whether it protects bone specifically during GLP-1 weight loss has not been tested. That protection is a reasonable inference, not a finding. For muscle, a 2019 meta-analysis of 12 trials found only a nonsignificant trend toward preserved lean mass with hormone therapy (5).

So I would not start hormones to protect muscle. I would protect muscle on purpose: protein at 80 to 120 grams a day, resistance training, and a bone density scan through her primary care provider when she qualifies. I do not routinely recommend multivitamins, so the effort goes into the food and the weights. If a woman already qualifies for hormone therapy, any skeletal benefit during weight loss is a bonus.

I can’t order a DXA scan myself, so that falls to the patient’s primary care provider. I recommend one if she is old enough to qualify, has a family history, or has another clinical reason, and I suggest she ask her primary care physician for it.

Naltrexone-bupropion and menopause

I use naltrexone only as naltrexone-bupropion (Contrave) for weight, and bupropion is where the menopause questions live.

Start with symptoms. In the Contrave label’s pooled trials, hot flush occurred in 4.2 percent versus 1.2 percent on placebo, hyperhidrosis in 2.6 versus 0.6 percent, and insomnia in 9.2 versus 5.9 percent (24). Those are three things a woman with perimenopausal night sweats already has too much of. The absolute numbers are small, but in fragile sleep they count. Nausea (32.5 versus 6.7 percent) and constipation (19.2 versus 7.2 percent) overlap with GLP-1 and oral estrogen effects (24).

Then safety. Contrave is contraindicated with a seizure disorder, bulimia or anorexia nervosa, chronic opioid use, uncontrolled hypertension, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptic drugs (24). That alcohol line matters in midlife, because a woman who uses wine to fall asleep and then quits cold to start a weight loss program is exactly who the label warns about. The label also notes increases in blood pressure and heart rate, so a home cuff reading before and after starting is reasonable (24). The Contrave label does not mention estrogen, but it asks for caution with drugs metabolized by CYP2D6, which is worth a medication-list check (24).

Bupropion and naltrexone can make it harder to sleep. For a woman who is already sleeping poorly in the middle of perimenopausal changes, I might lean toward a GLP-1 instead.

Where metformin fits

Metformin is the quiet one.

It has no FDA weight loss indication, and the effect is modest. A 2024 meta-analysis of 49 randomized trials in adults with overweight or obesity and no diabetes found a BMI reduction of about 0.56 kg/m2 against placebo, no significant difference from lifestyle modification alone, and low-quality trials overall (25). I prescribe it for weight when a GLP-1 is unwanted or unaffordable and naltrexone-bupropion is unwanted or contraindicated, always alongside diet and exercise.

Interactions are mild. The metformin label lists estrogens among drugs that tend to raise blood glucose, and long-term use can lower vitamin B12 (26). A 2025 review calls for randomized trials of metformin in perimenopausal women, since few exist (27).

Who should not combine them, or should wait?

A few situations call for pausing rather than prescribing at visit one. Unexplained vaginal bleeding comes first. The estradiol label lists undiagnosed abnormal genital bleeding as a contraindication, along with breast cancer history, estrogen-dependent neoplasia, active or past deep vein thrombosis or pulmonary embolism, recent stroke or heart attack, and liver disease (17). A personal or family history of medullary thyroid carcinoma or MEN 2 rules out Zepbound and Wegovy (1,2). A history of gallstones or pancreatitis calls for extra caution on the weight loss side, since the labels warn about both (1,2,13).

What about the boxed warning? In November 2025 the FDA announced it was removing the boxed warnings for cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels, while keeping the endometrial cancer warning on estrogen-alone products (28). The first six products were approved in February 2026 (29). Updates are rolling out batch by batch, and a generic estradiol tablet label posted this month still carries the older boxed language (17). The change shifts the tone of the conversation. It does not change the clot and gallbladder arithmetic above. The Menopause Society’s 2022 statement still describes a favorable benefit-risk balance for women under 60 or within 10 years of menopause onset, and a less favorable one beyond that (23).

For patients

Tell whoever prescribes your weight loss medication that you take hormones, and tell whoever prescribes your hormones what weight loss drug you are on. Those two conversations often happen on different platforms.

If you take estrogen by mouth and start a weekly injection or a pill like Foundayo, watch for hot flashes, mood swings or spotting returning in the first weeks and after each dose increase. Report it rather than assuming the hormones stopped working, and ask whether a patch, gel or spray makes sense. Know the warning signs of gallbladder trouble and clots: pain under the right ribs after eating, a swollen painful calf, sudden shortness of breath.

And do not ask for hormones to lose weight. Ask for them because your sleep, your sweats or your bones need them.

For clinicians

Three points to carry. First, the combination data are retrospective and confounded, so treat established indications as the reason to prescribe MHT and do not use it as an obesity drug (5,7). Second, default to transdermal estradiol when a woman has obesity, gallstone history or other thrombotic risk (15,16,18), and treat oral estrogen during GLP-1 titration as a time to watch for symptom recurrence, recognizing that the concern is extrapolated from contraceptive pharmacokinetics (1,11). Third, recheck TSH in anyone on levothyroxine, and ask about alcohol before prescribing bupropion (17,24).

One question colleagues ask: do the menopause and the weight get handled in the same visit? It depends on whether the patient wants to address the menopause symptoms or the weight first. The two are usually handled at separate visits. Sometimes I see the same patient for both, and sometimes a different clinician handles one of them, depending on scheduling and the patient’s preference.

The Bottom Line

Hormone therapy and weight loss medications can be taken together. The combination is plausible and not prohibited by the Zepbound or Wegovy labels, but the idea that hormones boost GLP-1 weight loss rests on small retrospective studies, and the randomized trial is still pending (3,4,7,8).

The real differences are practical. A patch or gel avoids the stomach-emptying problem behind the contraceptive advice on the Zepbound and Foundayo labels, and carries lower clot and gallbladder risk than oral estrogen, which matters because the weight loss drugs raise gallbladder risk too (1,13,15,18). Naltrexone-bupropion adds hot flashes, sweating and insomnia and is a poor fit for some midlife sleepers. Metformin changes little in either direction. Protect muscle with protein and lifting, and use hormones for menopause symptoms, not as a weight loss supplement.

Related Reading

Does Menopause Cause Weight Gain, or Is It Just Aging?
FDA Removes Black Box Warning From Menopause Hormone Therapy
Do Ozempic and Zepbound Cause Muscle Loss?
Foundayo vs. the Wegovy Pill: Comparing the Two New Weight Loss Pills
Why Can’t You Get an Estrogen Patch? The 2026 Estradiol Shortage, Explained
Should Women Take Testosterone After Menopause?
More on Menopause & Women’s Health

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources

1. ZEPBOUND (tirzepatide) prescribing information. DailyMed, Eli Lilly and Company. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
2. WEGOVY (semaglutide) injection and tablets prescribing information. DailyMed, Novo Nordisk. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
3. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4). https://pubmed.ncbi.nlm.nih.gov/38446869/
4. Mayo Clinic. New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause (Lancet Obstetrics, Gynaecology & Women’s Health, 2026). News release, January 22, 2026. https://www.eurekalert.org/news-releases/1113701
5. Clinical review: Menopause hormone therapy in weight management. Obesity Pillars. 2026 Jun. https://pmc.ncbi.nlm.nih.gov/articles/PMC13010941/
6. The Menopause Society. Hormone therapy may increase weight loss effectiveness of GLP-1s. Press release for the 2026 Annual Meeting. https://menopause.org/press-releases/hormone-therapy-may-increase-weight-loss-effectiveness-of-glp-1s
7. Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society. Maturitas. 2026 Oct. https://pubmed.ncbi.nlm.nih.gov/42664617/
8. ClinicalTrials.gov NCT06715514. Effects of combined menopausal hormone therapy and GLP-1 receptor agonist therapy on glucose and energy homeostasis in early postmenopausal women with or at risk of diabetes. https://clinicaltrials.gov/study/NCT06715514
9. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity. 2025. https://pubmed.ncbi.nlm.nih.gov/40074721/
10. Eli Lilly Medical. Can Zepbound (tirzepatide) be used with oral contraceptives or hormone replacement therapy? https://medical.lilly.com/us/products/answers/can-zepbound-tirzepatide-be-used-with-oral-contraceptives-or-hormone-replacement-therapy-211019
11. Tirzepatide and oral progestogens: a hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy. Maturitas. 2026 Sep. https://pubmed.ncbi.nlm.nih.gov/42721915/
12. Worsening vasomotor symptoms in the setting of estradiol and semaglutide: a case report. Menopause. 2025. https://pubmed.ncbi.nlm.nih.gov/40729307/
13. FOUNDAYO (orforglipron) tablets prescribing information. Eli Lilly and Company. https://uspl.lilly.com/foundayo/foundayo.html
14. Eli Lilly Medical. Can Foundayo (orforglipron) be used with contraceptives? https://medical.lilly.com/us/products/answers/can-foundayo-orforglipron-be-used-with-contraceptives-314529
15. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. https://pubmed.ncbi.nlm.nih.gov/30626577/
16. Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: a joint FIGO and WHF position paper. Global Heart. 2026. https://pubmed.ncbi.nlm.nih.gov/42799440/
17. Estradiol tablets, USP prescribing information. DailyMed (label posted October 2, 2026). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9333d92f-2585-4b99-aaea-87c01c95125e
18. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study (Million Women Study). BMJ. 2008;337:a386. https://pubmed.ncbi.nlm.nih.gov/18617493/
19. Thyroid dysfunction following tirzepatide use in a post-thyroidectomy patient on stable levothyroxine therapy: a case study. Cureus. 2026. https://pubmed.ncbi.nlm.nih.gov/42109981/
20. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/39996356/
21. GLP-1 receptor agonists and musculoskeletal outcomes: a systematic literature review and meta-analysis. Drugs. 2026. https://pubmed.ncbi.nlm.nih.gov/42730869/
22. Sex hormones mediate intensive lifestyle intervention-induced bone mineral density changes: Look AHEAD Sex Hormone Study. J Clin Endocrinol Metab. 2026. https://pubmed.ncbi.nlm.nih.gov/40576264/
23. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7). https://pubmed.ncbi.nlm.nih.gov/35797481/
24. CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b
25. The impact of metformin on weight and metabolic parameters in patients with obesity: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024. https://pubmed.ncbi.nlm.nih.gov/38468148/
26. Metformin hydrochloride extended-release tablets prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=356b02d0-d239-4441-bb33-c4c54166fcd7
27. Metformin use in prediabetes: a review of evidence and a focus on metabolic features among peri-menopausal women. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/40329646/
28. FDA. HHS advances women’s health, removes misleading FDA warnings on hormone replacement therapy. November 10, 2025. https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy
29. FDA. FDA approves labeling changes for menopausal hormone therapy products. February 12, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products